中国癌症杂志2026，Vol.36Issue(3)：278-289,12.DOI:10.19401/j.cnki.1007-3639.2026.03.008
BRAF V600E突变型转移性结直肠癌的分子生物学基础及治疗进展
Molecular biology basis and therapeutic advances in BRAF V600E-mutant metastatic colorectal cancer
周敬杰 1洪永刚 1刘鹏 1蒋慧 2尹小兰 3郝立强1
作者信息
- 1. 海军军医大学第一附属医院肛肠外科,上海 200433
- 2. 海军军医大学第一附属医院病理科,上海 200433
- 3. 上海大学附属四一一医院肿瘤中心,上海 200081
- 折叠
摘要
Abstract
Colorectal cancer(CRC)ranks as the common malignancy globally,with advanced-stage patients typically experiencing poor prognoses.Approximately 10%of metastatic CRC(mCRC)patients harbor the BRAF V600E mutation,which drives tumor invasion and metastasis by continuously activating the mitogen-activated protein kinase(MAPK)signaling pathway,leading to a significant reduction in the median survival time to 12-18 months.However,traditional chemotherapy has limited efficacy for these patients.In recent years,therapeutic strategies targeting the BRAF V600E mutation have been progressively explored.Multiple studies have made remarkable progress in improving patient prognosis through targeted therapy,immunotherapy,and their combined regimens.This review summarized the molecular mechanisms and therapeutic advances in BRAF V600E-mutant metastatic colorectal cancer,with a focus on the promising potential of combined targeted-immunotherapy regimens.关键词
结直肠癌/BRAF V600E突变/分子机制/靶向治疗/免疫治疗Key words
Colorectal cancer/BRAF V600E mutation/Molecular mechanisms/Targeted therapy/Immunotherapy分类
医药卫生引用本文复制引用
周敬杰,洪永刚,刘鹏,蒋慧,尹小兰,郝立强..BRAF V600E突变型转移性结直肠癌的分子生物学基础及治疗进展[J].中国癌症杂志,2026,36(3):278-289,12.
